LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $35,270 | -5.7% | 29,890 | +12.7% | 0.00% | – |
Q2 2023 | $37,393 | -91.1% | 26,520 | -90.5% | 0.00% | – |
Q1 2023 | $419,654 | +2447.7% | 279,769 | +1887.1% | 0.00% | – |
Q4 2022 | $16,472 | -3.1% | 14,079 | -9.0% | 0.00% | – |
Q3 2022 | $17,000 | -86.6% | 15,473 | -80.7% | 0.00% | – |
Q2 2022 | $127,000 | -35.2% | 80,169 | -37.1% | 0.00% | – |
Q1 2022 | $196,000 | -19.0% | 127,432 | +29.2% | 0.00% | – |
Q4 2021 | $242,000 | -1.2% | 98,659 | +1.6% | 0.00% | – |
Q3 2021 | $245,000 | +544.7% | 97,071 | +625.8% | 0.00% | – |
Q2 2021 | $38,000 | -91.9% | 13,374 | -93.3% | 0.00% | – |
Q1 2021 | $467,000 | +344.8% | 198,638 | +64.3% | 0.00% | – |
Q2 2020 | $105,000 | +94.4% | 120,899 | +84.0% | 0.00% | – |
Q1 2020 | $54,000 | -38.6% | 65,710 | -33.5% | 0.00% | – |
Q4 2019 | $88,000 | +100.0% | 98,833 | +119.1% | 0.00% | – |
Q3 2019 | $44,000 | – | 45,112 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,935,485 | $39,477,000 | 3.01% |
Raffles Associates | 2,080,536 | $2,351,000 | 2.51% |
Defender Capital, LLC. | 5,184,035 | $5,862,000 | 2.30% |
Prescott General Partners LLC | 1,851,851 | $2,093,000 | 0.16% |
DAFNA Capital Management LLC | 140,000 | $158,000 | 0.04% |
Fort Sheridan Advisors LLC | 83,931 | $95,000 | 0.03% |
Long Focus Capital Management, LLC | 215,000 | $243,000 | 0.02% |
XTX Topco Ltd | 72,807 | $82,000 | 0.02% |
Ergoteles LLC | 490,895 | $555,000 | 0.02% |
Beirne Wealth Consulting Services, LLC | 45,000 | $51,000 | 0.02% |